MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
MorphoSys AG announced the formation of a new alliance with Daiichi Sankyo Company, Limited in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys's first collaborator for HuCAL PLATINUM®-based drug discovery in infectious diseases.
Under the terms of the agreement, MorphoSys and Daiichi Sankyo will collaboratively apply HuCAL PLATINUM. The companies will jointly apply established as well as novel approaches to generate optimized, fully human therapeutic antibodies against targets associated with nosocomial infections. Daiichi Sankyo will also commit to funding the development of certain infectious disease specific technology at MorphoSys, which will be used to identify the most effective antibody-based drugs.
Total payments under the agreement include committed license fees and R&D funding in addition to success-based development milestones. MorphoSys also stands to receive royalties on sales of marketed drugs emerging from the collaboration.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
The Pink Gene

Giant Viruses Infect Deadly Parasite - New unusual giant virus discovered in wastewater treatment plant

Nobel Prize for Physiology or Medicine 2019 Announced
Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials
AMSBIO Announces US Office
TRIANNI & the German Society for Immunology (DGfI) honors outstanding young scientists.
4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat
Orphan drug designation for treatment against lung infections by Axentis Pharma AG
Abbott Opens Asia-Pacific Nutrition Research & Development Center in Singapore
Innovative Research on Manufacturing of Viral Vaccines and Gene Therapies - "Innovation Prize 2021 of the German BioRegions" awarded to ContiVir
